A new study conducted at the Princess Margaret Cancer Centre in Toronto reports on a randomized phase II trial indicating that the addition of the Wee1 inhibitor adavosertib to gemcitabone "reduced the risk of disease progression and death in women with recurrent, platinum-resistant or -refractory ovarian cancer." The trial, conducted on 99 women between 2014-2018 showed a median overall survival increase of 4.2 months (11.4 vs. 7.2 months) in patients that were administered Wee1.
To read more about this trial, click here.
No comments:
Post a Comment